Argitalpenak (149) JAVIER RUIZ MARTINEZ argitalpenak

filter_list

2026

  1. Toward Harmonizing Quantification of Dopamine Neuron Imaging Biomarkers in Parkinson's Disease: The Centamine Scale

    Annals of Neurology

2025

  1. Brain Atrophy Does Not Predict Clinical Progression in Progressive Supranuclear Palsy

    Movement Disorders, Vol. 40, Núm. 11, pp. 2517-2530

  2. Characterization of visual cognition in pre-manifest, manifest and reduced penetrance Huntington’s disease

    Scientific Reports, Vol. 15, Núm. 1

  3. Correction to: Heterogeneity of cognitive progression and clinical predictors in Parkinson’s disease–subjective cognitive decline (Journal of Neurology, (2025), 272, 3, (246), 10.1007/s00415-024-12808-0)

    Journal of Neurology

  4. Cortical volumetry and longitudinal cognitive changes in Parkinson’s disease: insights from the COPPADIS cohort

    Brain Imaging and Behavior, Vol. 19, Núm. 5, pp. 1048-1060

  5. Device-aided therapies (DATs) in Parkinson's disease (PD). The DATs-PD GETM Spanish Registry Protocol Study

    PLoS ONE, Vol. 20, Núm. 3 March

  6. Dynamics of retinal changes in early-stage Parkinson's disease

    Acta neuropathologica communications, Vol. 13, Núm. 1, pp. 20

  7. Dysphagia in Parkinson´s disease. A 5-year follow-up study

    Neurological Sciences, Vol. 46, Núm. 6, pp. 2637-2653

  8. Heterogeneity of cognitive progression and clinical predictors in Parkinson’s disease–subjective cognitive decline

    Journal of Neurology, Vol. 272, Núm. 3

  9. Impact of device-aided therapies on quality of life in patients with Parkinson’s disease. A comparative multicenter observational study

    Journal of Neural Transmission

  10. In-depth mass-spectrometry reveals phospho-RAB12 as a blood biomarker of G2019S LRRK2-driven Parkinson's disease

    Brain, Vol. 148, Núm. 6, pp. 2075-2092

  11. Influence of the level of education on cognitive function in Parkinson’s disease

    Journal of Neural Transmission

  12. Involvement of the Superior Cerebellar Peduncles in GAA- FGF14 Ataxia

    Neurology: Genetics, Vol. 11, Núm. 2

  13. LRRK2-associated parkinsonism with and without in vivo evidence of alpha-synuclein aggregates: longitudinal clinical and biomarker characterization

    Brain Communications, Vol. 7, Núm. 2

  14. Neuronal α-Synuclein Disease Stage Progression over 5 Years

    Movement Disorders, Vol. 40, Núm. 7, pp. 1318-1330

  15. Parkinson’s disease medication adjustments based on wearable device information compared to other methods: randomized clinical trial

    npj Parkinson's Disease, Vol. 11, Núm. 1

  16. Profile of People With Parkinson's Disease Treated With a Device-Aided Therapy in Spain. A Comparative Multicenter Observational Study

    Movement Disorders Clinical Practice

2024

  1. A potential patient stratification biomarker for Parkinson´s disease based on LRRK2 kinase-mediated centrosomal alterations in peripheral blood-derived cells

    npj Parkinson's Disease, Vol. 10, Núm. 1

  2. Association of retinal neurodegeneration with the progression of cognitive decline in Parkinson’s disease

    npj Parkinson's Disease, Vol. 10, Núm. 1

  3. Further Evidence of Cerebellar Cognitive Affective/Schmahmann Syndrome in RFC1-Related Syndrome

    Movement Disorders